About jasper therapeutics inc - JSPR
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.
JSPR At a Glance
Jasper Therapeutics, Inc.
2200 Bridge Parkway
Redwood City, California 94065
| Phone | 1-650-549-1400 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -75,801,000.00 | |
| Sector | Health Technology | Employees | 22 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
JSPR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 12.342 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.096 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.162 |
JSPR Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,445,500.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
JSPR Liquidity
| Current Ratio | 2.625 |
| Quick Ratio | 2.625 |
| Cash Ratio | 2.174 |
JSPR Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -131.055 |
| Return on Equity | -230.311 |
| Return on Total Capital | -1,407.371 |
| Return on Invested Capital | -227.805 |
JSPR Capital Structure
| Total Debt to Total Equity | 29.752 |
| Total Debt to Total Capital | 22.93 |
| Total Debt to Total Assets | 3.452 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |